Category - Developments

Developments

BioLineRx initiates Phase 2 first-line metastatic pancreatic cancer trial

BioLineRx (NASDAQ:BLRX) launched a Phase 2 trial evaluating motixafortide, in combination with cemiplimab and standard-of-care chemotherapy, in first-line metastatic pancreatic ductal adenocarcinoma (PDAC)...

October 29, 2020

Developments

MediWound completes enrollment in Phase 3 pediatric burn study

MediWound (NASDAQ:MDWD) completed enrollment in a Phase 3 study evaluating NexoBrid for the treatment of burns in patients 18 years of age and younger. NexoBrid is a topically administered biological product that...

October 29, 2020

Developments

IntelGenx inks binding LOI with Heritage for cannabis filmstrip supply

IntelGenx (TSXV:IGX; OTCQB:IGXT) signed a binding letter of intent (LOI) with Heritage Cannabis (CSE:CANN; OTCQX:HERTF) for the supply of CBD-containing filmstrip products for the Canadian and Australian markets. Under...

October 29, 2020

Developments

Titan Pharma to acquire JT-09 to develop ProNeura-based chronic pruritus treatment

Titan Pharmaceuticals (NASDAQ:TTNP) inked an agreement to acquire JT Pharmaceuticals’ kappa opioid agonist peptide, JT-09, for use in combination with Titan’s ProNeura long-term, continuous drug delivery technology, for...

October 28, 2020

Developments

Prevail Therapeutics gets FDA fast track designation for Gaucher disease

Prevail Therapeutics’ (NASDAQ:PRVL) PR001 received FDA fast track designation for the treatment of neuronopathic Gaucher disease. Gaucher disease is a lysosomal storage disorder caused by mutations in the...

October 27, 2020

Developments

Taysha gets FDA rare pediatric and orphan drug designations for Leigh syndrome

Taysha Gene Therapies (NASDAQ:TSHA) received FDA rare pediatric and orphan drug designations for TSHA-104 for the treatment of SURF1-associated Leigh syndrome. Leigh syndrome is a severe neurological disorder that...

October 27, 2020

Developments

Imagin Medical reports agenda for KOL virtual investor event on Oct. 29

Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) reported the agenda for its KOL virtual investor event taking place on Oct. 29 at 12:00 pm ET. Presenters include Jim Hutchens, Imagin’s...

October 26, 2020

Developments

Hepion to present on therapeutic approaches to COVID-19; NASH at Oct. 28; Oct. 29 events

Hepion Pharmaceuticals (NASDAQ:HEPA) will present virtually at the Roth Capital “therapeutic approaches for COVID-19” event taking place on Oct. 28 from 9:00 am to 1:20 pm ET; and at the B. Riley Securities...

October 26, 2020

Developments

Titan Pharma in debt settlement pact with Molteni and Horizon

Titan Pharmaceuticals (NASDAQ:TTNP) inked an agreement to settle all of its debt obligations with Molteni & C. dei F.lli Alitti Società di Esercizio and Horizon Credit. The debt was secured with a lien on all assets...

October 26, 2020

Developments

Kezar KZR-616 gets FDA orphan drug designations for two autoimmune disease

Kezar Life Sciences’ (NASDAQ:KZR) KZR-616 received FDA orphan drug designation for the treatment of polymyositis and dermatomyositis, autoimmune inflammatory myopathies with marked morbidity and mortality. KZR-616 is a...

October 23, 2020

Category - Developments

BioLineRx initiates Phase 2 first-line metastatic pancreatic cancer trial

MediWound completes enrollment in Phase 3 pediatric burn study

IntelGenx inks binding LOI with Heritage for cannabis filmstrip supply

Titan Pharma to acquire JT-09 to develop ProNeura-based chronic pruritus treatment

Prevail Therapeutics gets FDA fast track designation for Gaucher disease

Taysha gets FDA rare pediatric and orphan drug designations for Leigh syndrome

Imagin Medical reports agenda for KOL virtual investor event on Oct. 29

Hepion to present on therapeutic approaches to COVID-19; NASH at Oct. 28; Oct. 29 events

Titan Pharma in debt settlement pact with Molteni and Horizon

Kezar KZR-616 gets FDA orphan drug designations for two autoimmune disease

General

More